The Global Omega 3 Ingredients Market was valued at US$ 3.83 billion in 2016. Omega 3 ingredients are naturally-occurring polyunsaturated fatty acids and nutrients that are essential for human health. There are three types of omega 3 ingredients, namely alpha-linoleic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Increasing cardiovascular disease and growing demand for supplements, especially in North America and Europe is surging demand for DHA and EPA. Consumers are increasingly inclined towards food rich in omega 3 fatty and also supplements containing the acid, due to increasing awareness about the various health benefits associated with the same. Cold water fish are the primary source of omega 3 fatty acids and have various health benefits such effective treatment of hypertriglyceridemia and other cardiovascular diseases. This in turn creates a highly conducive environment for growth of the global omega-3 market.
To know the latest trends and insights prevalent in this market, click the link below:
Increasing life expectancy is increasing the incidence of lifestyle and age-related diseases and conditions such as high blood pressure, diabetes, obesity, and cholesterol. This in turn, is increasing the demand for healthy lifestyles and diet plans to ensure optimum calorie intake and nutrition to help avoid the contraction of diseases. This in turn, is increasing demand for omega 3 ingredients, thus boosting growth of the omega 3 ingredients market. The U.S. and Japan hold the largest markets for omega 3 ingredients, owing to high disposable income and relatively high health awareness among the populace in these countries in comparison to others. China, India, and Brazil are emerging economies account for high growth potential in the omega 3 ingredients market. Germany and Israel have emerged as the key innovation hubs of the omega 3 ingredients industry. In Germany, Royal DSM and Evonik entered into a joint venture in March 8, 2017 for obtaining omega 3 fatty acid products from natural marine algae for animal nutrition. Development of new products and product launches are expected to boost demand for omega 3 fatty acids as a means of obtaining animal nutrition without using fish oil. Also, in May 6, 2014, AstraZeneca received approval of Epanova (omega 3 carboxylic acid), from U.S. Food and Drug Administration (FDA), as indicated for lowering triglyceride levels with severe hypertriglyceridemia.
Key takeaways of the market: